NLTX vs. PLRX, BCAX, PRTA, DNTH, CRMD, QURE, ETNB, CGEM, LENZ, and PHAR
Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Pliant Therapeutics (PLRX), Bicara Therapeutics (BCAX), Prothena (PRTA), Dianthus Therapeutics (DNTH), CorMedix (CRMD), uniQure (QURE), 89bio (ETNB), Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry.
Neoleukin Therapeutics vs.
Neoleukin Therapeutics (NASDAQ:NLTX) and Pliant Therapeutics (NASDAQ:PLRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
In the previous week, Pliant Therapeutics had 5 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Pliant Therapeutics and 1 mentions for Neoleukin Therapeutics. Pliant Therapeutics' average media sentiment score of 0.22 beat Neoleukin Therapeutics' score of 0.00 indicating that Pliant Therapeutics is being referred to more favorably in the news media.
Pliant Therapeutics received 25 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 74.26% of users gave Pliant Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Pliant Therapeutics has a consensus price target of $40.50, suggesting a potential upside of 261.28%. Given Pliant Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Pliant Therapeutics is more favorable than Neoleukin Therapeutics.
Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
Neoleukin Therapeutics' return on equity of -37.22% beat Pliant Therapeutics' return on equity.
Neoleukin Therapeutics has higher earnings, but lower revenue than Pliant Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Pliant Therapeutics beats Neoleukin Therapeutics on 12 of the 17 factors compared between the two stocks.
Get Neoleukin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neoleukin Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NLTX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free NLTX Stock Alerts